Clinical advance in systemic chemotherapy for primary liver cancer
10.3781/j.issn.1000-7431.2014.01.015
- Author:
Ge-Liang YANG
1
Author Information
1. Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University
- Publication Type:Journal Article
- Keywords:
Antineoplastic protocols;
Drug therapy, combination;
Liver neoplasms;
Target therapy
- From:
Tumor
2014;34(1):91-96
- CountryChina
- Language:Chinese
-
Abstract:
Primary liver cancer (PLC) is one kind of common malignant tumor. Due to its low rate of early diagnosis, most patients are preliminarily diagnosed of advanced cancer and have lost opportunities for radical surgery. Currently, the integrated treatment is applied to improve the prognosis of these patients and prolong the survival time. Recently, more attentions have been paid to systemic chemotherapy with the development of new generation of chemotherapeutic agents and the targeted therapy. A large number of clinical trials have revealed that systemic chemotherapy plays an important role in the treatment of PLC, including prolonging the survival time, controlling the development of cancer and improving the quality of life. This review summarizes the advance in systemic chemotherapy for PLC and the related issues. Copyright© 2014 by TUMOR.
